Advertisement

Topics

FDA approves Vertex's Kalydeco for 600 CF patients with certain mutations

05:37 EDT 2 Aug 2017 | SmartBrief

The FDA has approved Kalydeco, or ivacaftor, for treatment of cystic fibrosis in more than 600 patients at least two years of -More

Original Article: FDA approves Vertex's Kalydeco for 600 CF patients with certain mutations

NEXT ARTICLE

More From BioPortfolio on "FDA approves Vertex's Kalydeco for 600 CF patients with certain mutations"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Cystic Fibrosis
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...